NASDAQHealth CareMedical DevicesSnapshot 2026-07-23
Reading LUNG? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment is characterized as a turnaround situation. LUNG is currently loss-making but has stable management and is navigating a challenging environment with high risks.
The market seems to have priced in a justified valuation, as LUNG is considered cheap compared to its peers. There is a notable expectations gap, indicating that the market may not fully anticipate the challenges ahead.
Fundamentals are likely to remain mixed in the near term. Management has set ambitious revenue and expense targets for 2026, but achieving these will require significant growth and tighter cost controls.
The thesis hinges on the performance of sector bellwethers like ABT, SYK, and MDT. If these companies continue to perform well, it could provide a favorable backdrop for LUNG. Conversely, any negative guidance from these peers could impact LUNG's trajectory.
Over the next 1 to 3 years, LUNG's performance will depend on management's ability to meet financial targets and the overall health of the healthcare sector. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Keeping this margin is important for making money. The company wants to control costs.
Confirms:Q2 gross margin is above 75%. This shows good cost management.
Disproves:Gross margin is below 75%. This suggests there may be cost problems.
Why it matters: Meeting revenue guidance is crucial for Pulmonx to show it can grow. This affects investor confidence.
Confirms:Q2 revenue reported at least $22.5M, on track for $90M to $92M annual guidance.
Disproves:Q2 revenue was below $22.5M. This shows challenges in meeting annual goals.
Why it matters: The earnings report will show if revenue growth is improving or still slowing. Investors will focus on this.
Confirms one read:The earnings report shows revenue growth speeding up. It is now above 10% year over year.
Confirms the other:Earnings report shows revenue growth below 5% year over year.
Why it matters: This would signal a recovery in sales after the recent declines. It is crucial to meet the annual revenue guidance of $90M to $92M.
Confirms:Q2 revenue growth is over 10% compared to last year. This shows a recovery.
Disproves:Q2 revenue growth is below 0%. This shows sales are still declining.
Why it matters: Staying within this range is crucial for financial health. It shows the company's ability to manage costs effectively.
Confirms:Operating expenses remain within the guided range of $113M to $115M.
Disproves:Operating expenses are over $115M. This shows challenges in managing costs.
